Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.80 |
| ▸ | EPHX1 | P07099 | 10/20 | 0.70 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.68 |
| ▸ | CASP2 | P42575 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.57 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.57 |
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003218 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL75904 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL2481694 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL14002535 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL8204709 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL25243376 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL7990903 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL559951 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL8979293 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL1457274 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116408203-A | Method for separating feldspar from photovoltaic glass quartz sand by lepidolite tailings | 合肥万泉非金属矿科技有限公司 | 2023-07-11 | — | — | CN | claimed |
| CN-109628758-A | A kind of extractant and its extracting process of elemental lithium | 虔东稀土集团股份有限公司 | 2019-04-16 | — | — | CN | claimed |
| CN-105837939-A | Composite antibacterial plastic for refrigerator and preparation method of composite antibacterial plastic | 宁波高新区夏远科技有限公司 | 2016-08-10 | — | — | CN | claimed |
| CN-101376929-A | Method for extracting bismuth from bismuth ore concentrate or material containing bismuth | UNIV CENTRAL SOUTH (CN) | 2009-03-04 | — | — | CN | claimed |
| EP-1042355-A1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2000-10-11 | — | — | EP | claimed |
| WO-1999033855-A1 | 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-07-08 | — | — | WO | claimed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2024009541-A1 | METHOD FOR PRODUCING WATER-ABSORBING RESIN COMPOSITION | ＳＤＰグローバル株式会社 | 2024-01-11 | — | — | WO | disclosed |
| US-11752086-B2 | Topical formulations and methods | MYOCEPT INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-116408203-A | Method for separating feldspar from photovoltaic glass quartz sand by lepidolite tailings | 合肥万泉非金属矿科技有限公司 | 2023-07-11 | — | — | CN | disclosed |
| WO-2023114937-A2 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | Acuitas Therapeutics, Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023091985-A1 | COMPOUNDS TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE | DTX PHARMA, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230162883-A1 | COMPOSITION AND METHOD | UNIV LIVERPOOL (GB) | 2023-05-25 | — | — | US | disclosed |
| EP-0455206-A1 | Compositions of liquid hydrocarbons originating from refining processes and showing improved low temperature properties | SOCIETA' ITALIANA ADDITIVI PER CARBURANTI S.r.l. (IT) | 1991-11-06 | — | — | EP | disclosed |
| US-4957917-A | Anti-inflammatory furanones | ALLERGAN, INC. (US) | 1990-09-18 | — | — | US | disclosed |
| EP-0369813-A2 | Anti-inflammatory furanones | ALLERGAN, INC (US) | 1990-05-23 | — | — | EP | disclosed |
| EP-0036560-B1 | FOAMABLE OLEFIN POLYMER COMPOSITIONS STABILIZED WITH N-ALKYL SUBSTITUTED AMIDES, FOAMING PROCESS USING THEM AND FOAM ARTICLE PRODUCED | THE DOW CHEMICAL COMPANY (US) | 1985-03-27 | — | — | EP | disclosed |
| US-4345041-A | Foaming synthetic resin compositions stabilized with N-(higher alkyl) C.sub. -C8 amides | ASAHI-DOW LIMITED (JP) | 1982-08-17 | — | — | US | disclosed |
| EP-0036560-A2 | Foamable olefin polymer compositions stabilized with N-alkyl substituted amides, foaming process using them and foam article produced | THE DOW CHEMICAL COMPANY (US) | 1981-09-30 | — | — | EP | disclosed |
| US-4251655-A | GASTRIC ACID ANTISECRETORY AGENTS | MCNEILAB, INC. (US) | 1981-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | KDM4E 2656/4885MAPK1 148/4885HIF1A 4148/4885 |
| US-11752086-B2 | Topical formulations and methods | KRT18, ANXA3, VIP | KDM4E 4065/4885MAPK1 4211/4885HIF1A 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.